Fetal Arrhythmias and Antiarrhythmic Therapy Across the Placenta

Fetal arrhythmias range from harmless isolated ectopic beats to sustained tachycardia or bradycardia that can impair cardiac output. The central clinical task is to identify the rhythm, assess its effect on the fetus and decide whether treatment is safer before birth than after delivery. In selected cases, medication given to the pregnant patient crosses the placenta and reaches the fetal circulation.

Transplacental antiarrhythmic therapy requires coordinated care between maternal-fetal medicine, fetal cardiology, neonatology, pharmacy and the referring maternity team. For families in Australia, that coordination may involve a tertiary centre in Sydney, Melbourne, Brisbane, Perth or Adelaide, with telehealth support for communities separated by long travel distances.

Recognising Fetal Rhythm Disturbance

A fetal heart rate outside the expected range is a finding, not a complete diagnosis. Persistent rates above about 180 beats per minute raise concern for tachyarrhythmia, while a sustained rate below about 110 beats per minute may indicate bradyarrhythmia. The rhythm pattern, atrial-to-ventricular relationship and degree of beat-to-beat variation are essential.

M-mode echocardiography and pulsed-wave Doppler can help establish whether atrial and ventricular contractions are coordinated. Supraventricular tachycardia commonly presents as a rapid, regular rhythm, while atrial flutter may show more atrial contractions than ventricular responses. Premature atrial contractions are often benign, although blocked ectopic beats can create an apparently slow fetal rate.

The clinical urgency increases when the rhythm is prolonged or accompanied by hydrops fetalis, ventricular dysfunction, cardiomegaly, tricuspid regurgitation or reduced fetal movement. Hydrops reflects fluid accumulation and may develop when sustained tachycardia compromises cardiac filling and output. A fetus with a stable rhythm and no cardiac deterioration may need surveillance, whereas a fetus with haemodynamic compromise may require prompt maternal treatment.

How Medicines Reach the Fetus

Transplacental treatment relies on a medicine reaching an effective concentration in fetal blood and cardiac tissue. The amount transferred depends on molecular size, protein binding, lipid solubility, placental transport, maternal metabolism, gestational age and placental function. Maternal dose and fetal response do not always move in parallel, so clinical monitoring remains more important than relying on a standard dose alone.

Digoxin, sotalol, flecainide and amiodarone are among the medicines used in specialist practice, with the choice influenced by rhythm mechanism, ventricular function, hydrops and maternal health. Digoxin may cross the placenta less effectively when hydrops is present. Flecainide can be useful for fetal supraventricular tachycardia, while sotalol may be considered for selected tachyarrhythmias but requires careful attention to QT prolongation and maternal renal function.

Treatment decisions should account for maternal electrocardiography, electrolytes, kidney and liver function, medication interactions and the likelihood of reaching therapeutic fetal levels. A drug that appears attractive pharmacologically may be unsuitable if it creates excessive maternal risk or cannot be monitored safely in the local setting. The goal is an effective fetal rhythm with the smallest reasonable exposure to both patients.

The wider perinatal context matters when planning any intervention. Evidence concerning antenatal corticosteroids, timing of birth and neonatal preparation should be considered separately from rhythm treatment; useful background is available in these updates on antenatal corticosteroid therapy, particularly when preterm delivery becomes a realistic possibility.

Selecting Treatment And Monitoring Response

A persistent fetal supraventricular tachycardia without hydrops may be managed with maternal digoxin, flecainide or sotalol, depending on the suspected mechanism and specialist preference. Some centres use combination therapy when the initial response is inadequate. Atrial flutter may respond differently from re-entrant supraventricular tachycardia, so rhythm diagnosis should guide the medicine rather than treating every rapid rate in the same way.

Amiodarone is generally reserved for difficult cases because of its long half-life and potential maternal and fetal adverse effects. It may have a role when other agents fail or when severe hydrops limits placental transfer of alternative drugs. Direct fetal therapy, including intramuscular or intraperitoneal administration, is uncommon and should be considered only by teams with the required expertise.

Monitoring usually includes serial ultrasound, assessment for hydrops, fetal echocardiography and maternal ECG review. The maternal pulse, blood pressure, symptoms, electrolytes and drug-specific toxicity markers may need regular checks. If a pregnant patient develops fainting, marked dizziness, chest pain, shortness of breath or a new irregular heartbeat, urgent assessment is required.

Antenatal corticosteroids may be indicated if preterm birth becomes likely, but they do not replace antiarrhythmic therapy and do not correct a fetal rhythm disorder. Similarly, delivery is not automatically the best response to tachycardia. If the fetus is preterm and treatment is controlling the rhythm, continuing pregnancy may avoid complications associated with premature birth.

Coordinating Care In Australia

In Australia, fetal arrhythmia management is usually concentrated in a tertiary perinatal service, with the local obstetric team continuing day-to-day support. A patient living outside a capital city may need repeated travel for fetal echocardiography, ECGs and medication review. Telehealth can reduce some journeys, although it cannot replace urgent ultrasound or hospital observation when the fetal condition changes.

The Therapeutic Goods Administration regulates medicines and the Poisons Standard, while prescribing practice is also shaped by state and territory requirements, hospital protocols and specialist governance. Several drugs used for fetal rhythm disorders may be prescribed outside their approved product indication. That makes clear documentation, informed consent, pharmacy review and communication with the maternity hospital particularly important.

Australian clinicians also need to consider Medicare access, private versus public referral pathways and the capacity of the nearest hospital to perform emergency caesarean birth or stabilise a premature newborn. A family in regional Queensland, Western Australia or northern New South Wales may require a planned transfer closer to a neonatal intensive care unit. Local weather, road distances and limited flight availability can affect timing, especially during periods of bushfire, flood or severe heat.

Perinatal outcomes are influenced by access to antenatal care, timely referral and disruptions to health services. The discussion of COVID-19 and global perinatal mortality is relevant because it shows how travel restrictions and strained systems can affect pregnancy care, even when the underlying fetal diagnosis is well understood. Families should receive a clear escalation plan, including where to attend after hours and when reduced fetal movement or maternal symptoms require immediate review.

Practical Safety Priorities

A structured pathway reduces avoidable delays and makes complex decisions easier to explain. The following priorities support safe use of maternal antiarrhythmic medicine:

• Confirm the fetal rhythm with ultrasound-based assessment before selecting therapy.
• Establish baseline maternal ECG, renal function, liver function and electrolyte results.
• Screen for structural heart disease, hydrops and ventricular dysfunction.
• Discuss expected benefits, uncertainties, off-label use and possible maternal toxicity.
• Arrange frequent fetal surveillance during dose changes and after rhythm conversion.
• Define transport, neonatal resuscitation and emergency delivery arrangements in advance.

Family communication should distinguish rhythm control from cure. A successful response may mean a slower ventricular rate, improved ventricular function and resolution of hydrops, yet recurrence can occur during dose reduction or later in pregnancy. Parents should know which symptoms matter, who will review results and whether they should present to their local maternity unit or travel directly to a tertiary hospital.

The delivery plan should be individualised. A fetus with controlled rhythm and no hydrops may remain in utero until a safer gestation, while persistent instability may require birth and neonatal treatment. After delivery, the newborn needs ECG assessment, observation for recurrent arrhythmia and review of any medicine that remains in the neonatal circulation.

Comparing Common Transplacental Options

No single antiarrhythmic is appropriate for every fetal rhythm. The table below summarises broad considerations rather than prescribing rules; dosing and sequencing must be determined by a fetal cardiology and maternal-fetal medicine team.

The most appropriate plan balances fetal benefit against maternal safety and the risks of prematurity. It may involve changing drugs, combining therapies, transferring care or preparing for neonatal treatment. Treatment should be reviewed whenever the rhythm, fetal condition or maternal clinical status changes.

Early referral gives the team time to confirm the diagnosis, obtain baseline investigations and plan access to medication and monitoring. Obstetricians, fetal cardiologists, neonatologists, pharmacists and local maternity clinicians should document one shared plan so that care remains consistent across hospitals and after-hours services.

Families and clinicians can support safer outcomes by seeking specialist assessment promptly when a persistent fetal rhythm abnormality is detected. A coordinated Australian care pathway, careful transplacental drug selection and regular maternal-fetal monitoring provide the best foundation for protecting both pregnant patient and baby.